期刊文献+

上海市儿童甲型H1N1流感病毒裂解疫苗接种不良反应评价 被引量:4

Evaluation of the Adverse Effects of Influenza Virus A(H1N1) Split Vaccine in Children and Adolescents in Shanghai
下载PDF
导出
摘要 目的:探讨上海市儿童接种国产甲型H1N1流感病毒裂解疫苗不良反应发生情况。方法:对本市中小学生接种甲型H1N1流感病毒裂解疫苗后,发生不良反应并来我院就诊的192例儿童进行观察记录。结果:所观察的发生不良反应的儿童中,男∶女比例为1.23∶1,年龄6~15岁。192例儿童患者中,接种当天和接种后第1天发生不良反应的分别为72例(37.5%)和70例(36.5%)。临床症状含发热的儿童176例(91.7%),高热51例。以全身伴呼吸系统症状的儿童最多,为181人。在明确记录恢复时间的149例儿童中,以就诊后3 d内恢复的为主,为101例(67.8%)。结论:国产甲型H1N1流感病毒裂解疫苗接种儿童后未出现严重不良反应,安全性较高。 Objective:To discuss the safety and occurrence of adverse reaction(ADR) of influenza virus A(H1N1) split vaccine after it had been used in children and adolescents in Shanghai. Methods:192 subjects with ADRs who had their H1N1 vaccine inoculation in our hospital were reviewed and recorded and their recovering process,followed up. Results:Among the children and adolescents(aged 6-15 years) with ADRs,gender ratio(M/F) was 1.23:1.In the 192 subjects with clear record of ADR occurring time,72(37.5%) occurred exactly on the day of while 70(36.5%) occurred on the day after vaccination.Fever was the most common clinical symptom(176,91.7%) and sometimes it could even be hyperpyrexia(51).Fever and respiratory symptoms occupied the maximum proportion among all kinds of ADRs.In 149 children and adolescents with clear record of recovery time,the majority(101,67.8%) were cured in 3 days after their visiting hospital.Conclusion:No severe adverse effects were found after the inoculation of domestic produced influenza virus A(H1N1) split vaccine,and it had its high safety in Chinese children and adolescents.
出处 《药物流行病学杂志》 CAS 2012年第9期428-431,共4页 Chinese Journal of Pharmacoepidemiology
关键词 甲型H1N1流感病毒裂解疫苗 药品不良反应 儿童 Influenza virus A(H1N1) split vaccine Adverse drug reaction Children
  • 相关文献

参考文献9

  • 1Dawood FS, Jain S, Finelli L, et al. Emergence of a novel swine-origin influenza A ( H1N1 ) virus in humans [ J]. N Engl J Meal,2009, 560 (25): 2605-2615.
  • 2Centers for Disease Control and Prevention (CDC). Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine [ J ]. MMWR Morb Mortal Wkly Rep, 2009, 58 ( 19 ) : 521-524.
  • 3Centers for Disease Control and Prevention(CDC). Update: influenza activity, United States, August 30, 2009-March 27, 2010, and composition of the 2010-11 influenza vaccine [J]. MMWR Morb Mortal Wkly Rep,2010,59(14) :423430.
  • 4何晓俐,康淑琼,龚成英,姜光瑶.3300例甲型H1N1流感疫苗接种者的安全性观察[J].中国循证医学杂志,2010,10(4):441-443. 被引量:7
  • 5Liang XF, Wang HQ, Wang JZ, et al. Safety and imrnunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial[ J ]. Lancet ,2010, 375 (9708) :56-66.
  • 6Lua CY, Shaoa PL, Changa LY, et al. Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents[ J]. Vaccine, 2010, 28 : 5864-5870.
  • 7Nolan T, McVernon J, Skeljo M, et al. Immunogenicity of a Monovalent 2009 Influenza A(H1N1 ) Vaccine in Infants and Children : a randomized trial [ J ]. JAMA,2010,303 ( 1 ) :37-46.
  • 8陈恩富,胡昱,凌罗亚,李倩,陈雅萍,戚小华,陈永弟.甲型H_1N_1流感疫苗的疑似预防接种异常反应监测[J].浙江预防医学,2010,22(5):1-3. 被引量:22
  • 9Cohen J. Vaccine policy. Immunizing kids against flumayprevent deaths among the elderly [ J ]. Science, 2004, 306 (5699) : 1123.

二级参考文献11

  • 1中华人民共和国卫生部.甲型H1N1流感医院感染控制技术指南.(2009-05-13)[2009-06-17].http://www.gov.cn/gzdt/2009-OS/13/content-1313569.Htm.
  • 2中华人民共和国卫生部.甲型H1N1流感诊疗方案[EB/OL].(2009-05-09)[2009-06-17].http://news.sina.C01.cnlc/2009-05-09/122817779540.shtml.
  • 3甲型H1N1流感疫苗该不该接种?.http://news.ximhuanet.com/politics/2009-11/02/content_12373651.htm.(2009-11-02).
  • 4甲型H1N1流感疫苗.百度百科.http://baike.Baidu.com/view/2572820.htm.
  • 5European Medicines Agency.Fifth pandemic pharmacovigilance weekly update[R].www.emea.europa.eu,6 January 2010.
  • 6Medicine and Healthcare Products Regulatory Agency.Suspected Adverse Drug Reaction(ADR) Analysis:Swine Flu Vaccines-H1N1(Celvapan and Pandemrix)[R].www.mhra.gov.uk,5 March 2009.
  • 7XiaoFeng Liang,HuaQing Wang,JunZhi Wang,et al.Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China:a multicentre,double-blind,randomised,placebo-controlled trial[J].Lancet,2010,375(9708):56-66.
  • 8FengCai Zhu,Hua Wang,HanHua Fang,et al.A Novel Influenza A (H1N1) Vaccine in Various Age Groups[J].N Engl J Med,2009,361(25):2414-2423.
  • 9Izurieta HS,Haber P,Wise RP,et al.Adverse events reported following live,cold-adapted,intranasal influenza vaccine[J].JAMA,2005,294(21):2720-2725.
  • 10陈先云,陈蜀岚.甲型H1N1流感医院感染的预防与控制对策[J].西部医学,2009,21(9):1502-1504. 被引量:8

共引文献26

同被引文献39

  • 1徐建荣,陈剑霞,叶众,陈子萌,陈磊.应急接种甲型H1N1流感疫苗免疫效果及疑似预防接种异常反应调查[J].中国公共卫生管理,2013,29(5):620-620. 被引量:2
  • 2张蕾,王永铭,陈斌艳,沈刚.儿童药物不良反应研究[J].中国临床药理学杂志,1996,12(1):39-45. 被引量:44
  • 3陈公平,连宁芳,金咏絮,等.化疗后老年非小细胞肺癌患者细胞免疫功能的变化[J].中国老年学杂志,2011,11(30):941-942.
  • 4An Advisory Committee Statement ( ACS), National Advisory Com- mittee on Immunization (NACI). Statement on seasonal influenza vaccine for 2013-2014 [ R]. Canada Communicable Disease Report. 2013, 39(ACS-4) : 1-37.
  • 5Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of in- fluenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices(ACIP) [ J]. MMWR Recomm Rep, 2010, 59 (RR-8) : 1-62.
  • 6Lorry GR, Myron JL, Ljuugman P,et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host [ J ]. Clini- cal Infectious Diseases Advance Access, 2013 : 1-57.
  • 7Anderson H, Petrie K, Berrisford C, et al. Seroconvcrsion after in- fluenza vaccination in patients with lung cancer [ J ]. Br J Cancer, 1999, 80:219-220.
  • 8Earle CC. Influenza vaccination in elderly patients with advanced colorectal cancer[ J ].J Clin Oncol. 2003. 21, 1161-1166.
  • 9王荣乐,赵庚昊,史强.北京儿童医院药物不良反应123例分析[J].中国实验方剂学杂志,2010,16(4):176-177. 被引量:20
  • 10李国伟,陈巧格,宋彩娟,李锋.郑州市甲型H1N1流感疫苗接种不良反应分析及应对措施[J].临床医学,2010,30(10):31-33. 被引量:6

引证文献4

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部